Through strong partnerships with our sister manufacturing company, Vici is now able to provide Phase 3 clinical manufacturing services to support NDA programs. With this offering, Vici is able to offer a full range of integrated CDMO services starting from early phase cGMP API synthesis to support nonclinical toxicology and proof-of-concept studies, first-in-human formulation development and phase 1 clinical supplies manufacturing, phase 2 clinical supplies manufacturing, and now phase 3 clinical supplies manufacturing for non-sterile formulations. Clients will benefit from a US-based manufacturing location, an experienced technical and manufacturing team, excellent quality, and competitive pricing.